Form 4: Eli Lilly Executive Sells Shares Under 10b5-1 Trading Plan

Donald A. Zakrowski, SVP, Finance, & CAO of Eli Lilly, sold 750 shares of common stock at $819.47 per share on June 3, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Donald A. Zakrowski, a Senior Vice President at Eli Lilly, sold 750 shares of the company's common stock on June 3, 2024.
• The sale was executed at a price of $819.47 per share.
• This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 16, 2023.
• Following the transaction, Mr. Zakrowski directly owns 7,130 shares and indirectly owns 1,710 shares through a 401(k).

Sentiment

Score: 5

Explanation: The document is a routine filing of an executive stock sale under a pre-arranged plan, which is neither positive nor negative.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives to use 10b5-1 plans to manage their stock sales and avoid accusations of trading on inside information.

Comparison to Industry Standards

• Many executives at publicly traded companies use 10b5-1 trading plans to manage their stock sales.
• These plans are designed to comply with insider trading regulations and provide transparency.
• The sale by Mr. Zakrowski is consistent with standard practices for executives at large corporations like Eli Lilly.

Stakeholder Impact

• The stock sale by an executive may have a minor impact on shareholder sentiment, but is unlikely to significantly affect the stock price due to the pre-arranged nature of the sale.

Key Dates

Keywords

insider trading, Form 4, Rule 10b5-1, stock sale, executive, Eli Lilly, LLY